CONCLUSION: CNM-Au8 treatment improved long-term survival with decreased mortality risk >70% vs. original placebo randomization, and compared to ENCALS predicted median survival.

**Study Design Scheme**

- **36-Week Blinded Treatment Period with Long Term OLE**
  - Double-Blind Period
  - Long-Term Open Label Extension

**Participant Vital Status by Treatment Group**

- 23 assigned to CNM-Au8
- 22 assigned to Placebo
- 22 completed 36-week Treatment Period (96%)
- 19 completed 36-week Treatment Period (90%)

**Notes:**
- Time to all-cause mortality amongst participants originally randomized to CNM-Au8 compared to participants originally randomized to placebo through 31-Aug-2022. Vital status and data of death (if applicable) were captured for all subjects withdrawn from the study. Last-to-follow-up (active, n=1; placebo, n=1) censored at the date of last study contact (Active: Feb-2021; Placebo: Feb-2022).
- All OLE ex-placebo CNM-Au8 transitioned participants within the placebo group. All alive subjects are right censored as of 31-Aug-2022.

Acknowledgements: We thank the ALS study patients and their families for their support and willingness to engage in clinical research. We thank the site investigators for their research excellence and dedication to patients. We thank FightMND of Australia for substantially funding the RESCUE-ALS trial.